3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Breast Neoplasms
41
Carcinoma, Renal Cell
31
Neoplasms
18
Kidney Neoplasms
17
Neuroendocrine Tumors
16
Neoplasm Metastasis
13
Tuberous Sclerosis
10
Prostatic Neoplasms
8
Carcinoma
8
Lymphoma, Mantle-Cell
7
Lymphoma, Large B-Cell, Diffuse
7
Hodgkin Disease
7
Glioma
7
Glioblastoma
7
Astrocytoma
7
Waldenstrom Macroglobulinemia
6
Triple Negative Breast Neoplasms
6
Recurrence
6
Lymphoma
6
Head and Neck Neoplasms
6
Stomach Neoplasms
5
Ovarian Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Neuroendocrine
5
Brain Neoplasms
5
Sezary Syndrome
4
Sarcoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Pancreatic Neoplasms
4
Mycosis Fungoides
4
Interventions
Octreotide
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Malignant Carcinoid Syndrome
×
Everolimus
×
Clear all
NCT00412061
2014-11-21
RADIANT-2
Novartis
Phase 3
Completed
429 enrolled
13 charts